Investment Rating - The report maintains an "Outperform" rating for the company [2][8]. Core Insights - The company reported a revenue of 562 million yuan for H1 2025, a year-on-year increase of 10.9%, but a significant decline in net profit by 67.9% to 15 million yuan [5][8]. - The Q2 2025 revenue was 369 million yuan, reflecting a 4.3% year-on-year growth, while net profit dropped by 91.3% to 3 million yuan, indicating that revenue met market expectations but profits fell short [5][8]. - The company aims to improve profitability in H2 2025 through various measures, including increasing the sales proportion of high-margin products and enhancing cost management [8]. Financial Data and Profit Forecast - The company’s total revenue projections for 2025-2027 are adjusted to 1.28 billion yuan, 1.61 billion yuan, and 2.05 billion yuan respectively, with corresponding net profits of 95 million yuan, 112 million yuan, and 151 million yuan [7][8]. - The gross margin for H1 2025 was reported at 32.2%, a decrease of 9.3 percentage points year-on-year, while the net margin was 2.7%, down 6.6 percentage points [8]. - The company’s earnings per share (EPS) for 2025 is projected at 0.77 yuan, with a price-to-earnings (PE) ratio of 28 [7][8]. Business Performance - The core business segments showed varied performance, with sports nutrition products growing by 24.7% year-on-year, while military supply and other segments faced declines [8]. - The company’s protein muscle gain products generated 327 million yuan in revenue for H1 2025, a 29.1% increase, despite overall market challenges [8]. - The energy supplement segment is expanding, with a notable 9.2% increase in revenue from energy gels [8]. Strategic Outlook - The company plans to enhance its product structure and cost management to counteract declining net profit margins [8]. - New channel development and market expansion efforts are underway to adapt to the evolving sports nutrition consumer landscape [8].
康比特（833429）：Q2毛利率显著承压，H2多措并举改善盈利能力